Scienza e Tecnologia
HER2DX® RECOGNIZED BY TIME AS ONE OF THE BEST INVENTIONS OF 2022
HER2DX has been recognized as one of the top inventions in the category, which highlights cutting-edge innovations that are successfully incorporated into clinical practice and provide patients with good outcomes.
Regarding HER2DX , the publication said: "
says .
adds: " "
This year's edition of the awards highlights inventions that made a big impact between November 2021 and September 2022 , including HER2DX , which was brought to market in the year.
To compile the list, TIME solicited nominations from TIME's editors and correspondents around the world, and through an online application process, paying special attention to growing fields—such as the electric vehicle industry, green energy, and the metaverse. TIME then evaluated each contender on a number of key factors, including originality, efficacy, ambition, and impact.
The full list of winners is published both printed and online - TIME has a worldwide readership of over 100 million- as well as on social media, including Twitter, where they have 18 million followers, Facebook (13 million fans) and Instagram (11 million followers), together estimated to generate 650 million impressions in the media around the world.
HER2DX is the world's first diagnostic test formulated specifically for HER2+ breast cancer. Marketed by REVEAL GENOMICS since
January 2022 , the HER2DX is a standardized 27-gene expression test for patients with early-stage HER2+ breast cancer.
HER2DX is a prognostic, predictive assay based on clinical and genomic data. The test integrates clinical information (i.e., tumor size and nodal status) with biological information tracking immune response, luminal differentiation, tumor cell proliferation, and expression of the HER2 17q12-21 chromosomal amplicon, including the ERBB2 gene.
HER2DX predicts:
REVEAL GENOMICS, S.L. is a biotechnology start-up seeking to change the way biomarkers are used in oncology. It is focused on developing innovative diagnostic tools to define the best therapeutic options for patients with cancer. The company uses pioneering techniques, sophisticated computer applications, and machine learning to reveal new cancer research data.
REVEAL GENOMICS, S.L. is a spin-off of Hospital Clínic of Barcelona , IDIBAPS, University of Barcelona (U.B.), and Vall d'Hebrón Institute of Oncology (VHIO).
REVEAL GENOMICS and HER2DX are registered trademarks of REVEAL GENOMICS, S.L.
Web: . Twitter:
Adriana Herrera , aherrera@reveal-genomics.com
Logo - https://mma.prnewswire.com/media/1944124/HER2DX_Logo.jpg
View original content to download multimedia:https://www.prnewswire.co.uk/news-releases/her2dx-recognized-by-time-as-one-of-the-best-inventions-of-2022-301674741.html